Machine Learning Uncovers Adverse Drug Effects on Intestinal Bacteria.
Laura E McCoubreyMoe ElbadawiMine OrluSimon GaisfordAbdul W BasitPublished in: Pharmaceutics (2021)
The human gut microbiome, composed of trillions of microorganisms, plays an essential role in human health. Many factors shape gut microbiome composition over the life span, including changes to diet, lifestyle, and medication use. Though not routinely tested during drug development, drugs can exert profound effects on the gut microbiome, potentially altering its functions and promoting disease. This study develops a machine learning (ML) model to predict whether drugs will impair the growth of 40 gut bacterial strains. Trained on over 18,600 drug-bacteria interactions, 13 distinct ML models are built and compared, including tree-based, ensemble, and artificial neural network techniques. Following hyperparameter tuning and multi-metric evaluation, a lead ML model is selected: a tuned extra trees algorithm with performances of AUROC: 0.857 (±0.014), recall: 0.587 (±0.063), precision: 0.800 (±0.053), and f1: 0.666 (±0.042). This model can be used by the pharmaceutical industry during drug development and could even be adapted for use in clinical settings.
Keyphrases
- machine learning
- neural network
- adverse drug
- human health
- risk assessment
- physical activity
- escherichia coli
- endothelial cells
- weight loss
- artificial intelligence
- drug induced
- big data
- climate change
- emergency department
- deep learning
- electronic health record
- body composition
- intellectual disability
- convolutional neural network